W

ASHINGTON — Two weeks ago, Dr. Joseph Gulfo ran a panel at the Biotech Showcase in San Francisco titled, “The Trump Administration: What to expect from the FDA.”

He left out one key detail: He may end up running the place.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Gulfo would be a terrific choice. He’s knowledgeable, has long experience in both academic and industry, and has the fire in the belly for reform.

  • What is his position on device approvals and safety? Would he keep the current outdated “one type fits all” system, or move to a framework for Precision Devices, with prescreening patients for immune reactivity to determine if device materials are “right for you” before being installed?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy